Neuropathologic and Neurochemical Imaging Technologies and Their Clinical Applications in Alzheimer's Disease

Phase 1 and Phase 2 clinical trials for the evaluation of pharmacokinetics, safety, and efficacy of SNUBH-NM-333(18F), a new diagnostic radiopharmaceutical for PET imaging of amyloid plaques, in Alzheimer's disease patients and healthy volunteers

Status

Recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

CRIS

Registry ID

KCT0000379

Enrollment

Registered

2012-03-12

Start date

2010-10-25

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Radiation : radiopharmaceutical: SNUBH-NM-333(18F) volume: 5~10CC number: 1 period: once injection route: intra vein subject: Alzheimer's disease patients, healthy volunteers

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Clinical Dementia Rating: over 0.5 NINCDS/ADRDA criteria probable Alzheimer's disease DSM-IV criteria Alzheimer's Disease

Exclusion criteria

Exclusion criteria: Evidence of delirium or confusion, other consciousness disorder Nuerologic disease that causes cognitive fuction decline(parkinson's disease, stroke, brain hemorrhage, cancer, normal pressure hydrocephalus etc.)

Design outcomes

Primary

Measure	Time frame
Pharmacokinetics of SNUBH-NM-333(18F), a new diagnostic radiopharmaceutical ;Safety of SNUBH-NM-333(18F), a new diagnostic radiopharmaceutical	—

Secondary

Measure	Time frame
Evaluation of adverse event after SNUBH-NM-333(18F) injection	—

Countries

Korea, Republic of

Contacts

Public ContactJi Shin

Seoul National University Hospital

Outcome results